Mutations of Fused in sarcoma (FUS), a ribonucleoprotein involved in RNA metabolism, have been found associated with both familial and sporadic cases of amyotrophic lateral sclerosis (ALS). Notably, besides mutations in the coding sequence, also mutations into the 3' untranslated region, leading to increased levels of the wild-type protein, have been associated with neuronal death and ALS pathology, in ALS models and patients. The mechanistic link between altered FUS levels and ALS-related neurodegeneration is far to be elucidated, as well as the consequences of elevated FUS levels in the modulation of the inflammatory response sustained by glial cells, a well-recognized player in ALS progression. Here, we studied the effect of wild-type FUS overexpression on the responsiveness of mouse and human neural progenitor-derived astrocytes to a pro-inflammatory stimulus (IL1β) used to mimic an inflammatory environment. We found that astrocytes with increased FUS levels were more sensitive to IL1β, as shown by their enhanced expression of inflammatory genes, compared with control astrocytes. Moreover, astrocytes overexpressing FUS promoted neuronal cell death and pro-inflammatory microglia activation. We conclude that overexpression of wild-type FUS intrinsically affects astrocyte reactivity and drives their properties toward pro-inflammatory and neurotoxic functions, suggesting that a non-cell autonomous mechanism can support neurodegeneration in FUS-mutated animals and patients.
Pubmed ID: 30872738 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
An Antibody supplier; Dako was purchased by Agilent in 2012 and several years later the websites began to reflect the Dako products as part of the Agilent catalog.
View all literature mentionsThis monoclonal targets GFAP (glial fibrillary acidic protein)
View all literature mentionsThis monoclonal targets S100 beta
View all literature mentionsThis polyclonal targets Microtubule-Associated Protein 2 (MAP2)
View all literature mentionsThis monoclonal targets βIII Tubulin
View all literature mentionsThis polyclonal targets Caspase 3 active (cleaved) form
View all literature mentionsThis monoclonal targets Nestin clone 10C2
View all literature mentionsThis monoclonal targets FUS/TLS (4H11)
View all literature mentionsThis monoclonal targets Human SOX2
View all literature mentionsThis polyclonal targets FLAG
View all literature mentionsThis monoclonal targets slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH
View all literature mentionsRattus norvegicus with name WI from RGD.
View all literature mentionsThis monoclonal targets slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH
View all literature mentionsThis monoclonal targets GFAP (glial fibrillary acidic protein)
View all literature mentionsThis monoclonal targets S100 beta
View all literature mentionsThis polyclonal targets Caspase 3 active (cleaved) form
View all literature mentionsThis monoclonal targets βIII Tubulin
View all literature mentionsThis monoclonal targets Nestin clone 10C2
View all literature mentionsThis polyclonal targets Microtubule-Associated Protein 2 (MAP2)
View all literature mentionsThis monoclonal targets FUS/TLS (4H11)
View all literature mentionsRattus norvegicus with name WI from RGD.
View all literature mentionsThis polyclonal targets FLAG
View all literature mentionsThis monoclonal targets Human SOX2
View all literature mentionsThis monoclonal targets βIII Tubulin
View all literature mentions